Multiresistente Erreger

Zusammenfassung

Infektionen, die durch multiresistente Erreger hervorgerufen werden, stellen ein zunehmendes Problem im medizinischen Alltag dar und gehen mit einer verlängerten Behandlungsdauer und einer erhöhten Mortalität einher. In den zurückliegenden Jahrzehnten lag das Hauptaugenmerk im Bereich multiresistenter Erreger auf dem bekanntesten Vertreter, dem Methicillin-resistenten Staphylococcus aureus (MRSA). In letzter Zeit haben jedoch resistente Gram-negative Erreger mit β-Laktamasen mit breitem Wirkspektrum (ESBL) und multiresistente Gram-negative Erreger (MRGN) zunehmend an Bedeutung gewonnen und stellen heute den Kliniker vor eine größere therapeutische Herausforderung als MRSA. Die vorliegende Arbeit gibt eine Übersicht über die Entstehung von Antibiotikaresistenz, die wichtigsten Erreger aus dem Gram-negativen und -positiven Keimspektrum, Clostridium difficile sowie Maßnahmen, um die Selektion resistenter Erreger zu reduzieren und deren Weiterverbreitung zu unterbinden.

Abstract

Infections caused by multidrug resistant (MDR) organisms are becoming more frequently in daily practice and are associated with an increase in duration of treatment and mortality. During the past decades, particular attention in the field of MDR pathogens was paid to methicillin-resistant staphylococcus aureus (MRSA). For the last years, MDR gram-negative organisms, with e.g., “extended-spectrum beta-lactamases” (ESBL), have been gaining a growing significance. Currently, treatment of infections with these organisms displays a greater challenge for the clinician compared to MRSA infections. This review illustrates the emergence of antibiotic resistance, provides information on the most important gram-negative and gram-positive bacteria, Clostridium difficile and measures to prevent their further spread.

Schlüsselwörter

Antibiotikatherapie - Infektion - multiresistente Erreger

Key words

antibiotic treatment - infection - multiresistant organisms

• Literatur

• 1 Boucher HW, Talbot GH, Bradley JS et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12
• 2 Weiss G, Tammer I, Wolff S. [Antibiotic resistance: development in surgical intensive care]. Zentralbl Chir 2011; 136: 143-151
• 3 DʼCosta VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 2011; 477: 457-461
• 4 Harbarth S. Einfluss des Antibiotikaverbrauchs auf Resistenzbildung und -selektion. AINS Anästhesiol Intensivmed Notfallmed Schmerzther 2007; 42: 130-135
• 5 Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998; 317: 657-660
• 6 Cosgrove SE, Kaye KS, Eliopoulous GM et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 185-190
• 7 Nilsson AI, Berg OG, Aspevall O et al. Biological Costs and Mechanisms of Fosfomycin Resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-2858
• 8 Bonten MJM, Mascini EM. The hidden faces of the epidemiology of antibiotic resistance. Intensive Care Med 2003; 29: 1-2
• 9 Overdevest I, Willemsen I, Rijnsburger M et al. Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerging Infect Dis 2011; 17: 1216-1222
• 10 Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 2011; 17: 873-880
• 11 Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to “critically important” antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501-1506
• 12 Harbarth S, Liassine N, Dharan S et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-1385
• 13 Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368: 874-885
• 14 Stone SP, Fuller C, Savage J et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ 2012; 344: e3005
• 15 Anonym.. 1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf.. Available at: http://ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf Stand: 29.10.2012
• 16 Meyer E, Schwab F, Schroeren-Boersch B et al. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 2010; 14: R113
• 17 Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010; 11: 79-109
• 18 Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-327
• 19 Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-151
• 20 Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45 (Suppl. 03) S184-S190
• 21 Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010; 36: 391-400
• 22 Borde J, Kern W. Therapie von MRSA-Infektionen. Dtsch Med Wochenschr 2012; 137: 2553-2557
• 23 Huebner J, Dettenkofer M, Kern WV. Vancomycin-resistant enterococcus. Dtsch Med Wochenschr 2005; 130: 2463-2468
• 24 Chatterjee I, Iredell JR, Woods M et al. The implications of enterococci for the intensive care unit. Crit Care Resusc 2007; 9: 69-75
• 25 Reuken PA, Pletz MW, Baier M et al. Emergence of spontaneous bacterial peritonitis due to enterococci – risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther 2012; 35: 1199-1208
• 26 Bodmann KF. Komplizierte intraabdominelle Infektionen: Erreger, Resistenzen. Der Chirurg 2010; 81: 38-49
• 27 Gorbach SL. Intraabdominal infections. Clin Infect Dis 1993; 17: 961-965
• 28 Robert Koch-Institut. Definition der Multiresistenz gegenüber Antibiotika bei gramnegativen Stäbchen im Hinblick auf Maßnahmen zur Vermeidung der Weiterverbreitung. Epidemiologisches Bulletin 2011; 36: 335-339
• 29 Gatermann S, Chaberny IF, Pletz M et al. Multiresistente pulmonale Erreger auf der Intensivstation. Der Pneumologe 2010; 7: 412-422
• 30 Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 (Suppl. 04) S341-S345
• 31 Paterson DL, Ko WC, von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140: 26-32
• 32 Arndt S, Lauf H, Weiß G et al. [Spectrum of microbial colonisation and resistance of a surgical ICU in a systematic comparison of the 10-year time period 1996 – 2005 using routine microbiological testing]. Zentralbl Chir 2011; 136: 152-158
• 33 Robert Koch-Institut. Nachweis von Carbapenemasen im Jahr 2010 – Bericht des NRZ für gramnegative Krankenhauserreger. Epidemiologisches Bulletin 2011; 32: 301-306
• 34 Livermore DM, Warner M, Mushtaq S et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-419
• 35 Kola A. Clostridium-difficile-Infektionen. Wie gefährlich sind die neuen Stämme?. Der Internist 2010; 51: 154-160
• 36 Rodemann JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344
• 37 Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210
• 38 Schneeweiss S, Korzenik J, Solomon DH et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264
• 39 Tschudin-Sutter S, Widmer AF, Perl TM. Clostridium difficile: novel insights on an incessantly challenging disease. Curr Opin Infect Dis 2012; 25: 405-411
• 40 Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079
• 41 Binion DG. Strategies for management of Clostridium difficile infection in immunosuppressed patients. Gastroenterol Hepatol (NY) 2011; 7: 750-752
• 42 Gerding DN, Muto CA, Owens RC. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl. 01) S32-S42
• 43 Ben-Horin S, Margalit M, Bossuyt P et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-987
• 44 Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002
• 45 Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile nfections. Clinical Therapeutics 2012; 34: 1-13
• 46 Snitkin ES, Zelazny AM, Thomas PJ et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012; 4: 148ra116
• 47 Hilty M, Betsch BY, Bögli-Stuber K et al. Transmission Dynamics of Extended-Spectrum β-lactamase-Producing Enterobacteriaceae in the Tertiary Care Hospital and the Household Setting. Clin Infect Dis 2012; 55: 967-975
• 48 Anonym Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2012; 55: 1311-1354
• 49 Dettenkofer M, Utzolino S, Luft D et al. [Effectiveness and risks of isolation precautions in patients with MRSA and other multidrug-resistant bacteria]. Zentralbl Chir 2010; 135: 124-128
• 50 Zweigner J, Schwab F, Gastmeier P. Rationale Antibiotikatherapie in der ambulanten medizinischen Versorgung. Krankenhaushygiene up2date 2012; 7: 183-197
• 51 Weber A, Schneider C, Grill E et al. [Interventions by clinical pharmacists on surgical wards–impact on antibiotic therapy]. Zentralbl Chir 2011; 136: 66-73